Articles
Histogen Doses First Patient In 1B/2A Trial – Update 6/2/20 Histogen has wasted no time in getting their latest trial of HST-001 (HSC) underway. On June 1, 2020, the company sent out a press release to announce the first male patient has been dosed in their latest trial of HSC. Positive developments seem to be…
Read More
Follicle Thought is pleased to present an exclusive look at a newcomer in the hair loss treatment industry, Triple Hair of Canada. Triple Hair’s Story Triple Hair was founded by Dr. Houfar Sekhavat, an opthalmologist based in Moncton, Canada. It was Dr. Sekhavat’s own experience with androgenic alopecia which lead him to seek out a…
Read More
Today, I’m happy to be sharing a “never seen online before” poster of a L’Oreal research project involving the creation of hair follicle organoids in a dish. This type of work is commonly referred to as “hair cloning” – the ability to create brand new hair follicles outside the body using various types of follicle…
Read More
Phase 2 Trial Of Topical FOL-005 Has Resumed- Update 6/9/20 After a nearly 3 month intermission due to coronavirus restraints, Follicum is now able to continue recruitment for its phase 2 trial of a topical FOL-005 formulation. In addition to restarting the trial, Follicum has enlisted a third study center, CentroDerm of Wuppertal, Germany, to…
Read More
Replicel Terminates License With Shiseido: Update (12/21/21) Two months after Replicel announced that it was entering arbitration proceedings with Shiseido, the company has announced today that it has terminated its license agreement with Shiseido. The license agreement between Replicel and Shiseido dates back to 2013 when Shiseido paid an upfront fee to gain the rights…
Read More
Histogen is finally becoming a publicly traded company in 2020 after latest merger deal. On January 28, 2020, Histogen and Conatus Pharmaceuticals issued a press release announcing a definitive merger agreement between the two companies. Like Histogen, Conatus Pharmaceuticals is a biotech company based in San Diego, CA. Conatus has been publicly traded on Nasdaq…
Read More
RT160 Gray Hair Reversal Published Study (7/13/20) Last week, a new peer-reviewed article on RiverTown Therapeutics’ RT1640 was published in the Pigment Cell & Melanoma Research journal. The study is titled “Topical RT1640 treatment effectively reverses gray hair and stem cell loss in a mouse model of radiation‐induced canities” and was led by Dr. Melissa…
Read More
2020 has started with some good news for people seeking hair regrowth treatments. HairClone announced today that they have been awarded a grant from the Innovate UK organization. This grant is government funded in the United Kingdom and is awarded to innovative technologies with the potential to make an impact on the UK economy. I’m…
Read MoreIn this article we will take a look at the most promising developments slated to occur in the hair restoration industry in 2020. Clinical Treatments And Drugs For Hair Loss In 2020 TissUse & J Hewitt – TissUse’s hair regeneration therapy is known as the Smart Hair Transplant or SHT which has been in development…
Read More
Updated 12/19/19 Today, I received an email from Follica management which shared the company’s latest press release. The company has just announced positive topline data from its FOL-004 safety and efficacy optimization study which was carried out in 2019. According to the release, the study was designed to determine the optimal treatment regimen involving Follica’s…
Read More